Oragenics, Inc.   Report issue

For profit Phase 2
Founded: Tampa FL United States (1996)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2012
NCT01520974
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Oragenics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ag013 (1 trial)

Drugs in Other Trials (1)

s. uberis kj2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mucositis (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2